American Century Companies Inc. Makes New Investment in Ginkgo Bioworks Holdings, Inc. $DNA

American Century Companies Inc. bought a new stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 33,279 shares of the company's stock, valued at approximately $190,000. American Century Companies Inc. owned approximately 0.06% of Ginkgo Bioworks as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. US Bancorp DE lifted its stake in shares of Ginkgo Bioworks by 43.5% in the first quarter. US Bancorp DE now owns 6,302 shares of the company's stock valued at $36,000 after purchasing an additional 1,911 shares during the period. CWM LLC lifted its stake in shares of Ginkgo Bioworks by 667.6% in the first quarter. CWM LLC now owns 12,274 shares of the company's stock valued at $70,000 after purchasing an additional 10,675 shares during the period. Fox Run Management L.L.C. acquired a new stake in shares of Ginkgo Bioworks in the first quarter valued at about $76,000. Green Alpha Advisors LLC lifted its stake in shares of Ginkgo Bioworks by 31.7% in the first quarter. Green Alpha Advisors LLC now owns 18,470 shares of the company's stock valued at $105,000 after purchasing an additional 4,449 shares during the period. Finally, Mercer Global Advisors Inc. ADV acquired a new stake in shares of Ginkgo Bioworks in the fourth quarter valued at about $116,000. Hedge funds and other institutional investors own 78.63% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on DNA. Cowen reiterated a "buy" rating on shares of Ginkgo Bioworks in a research note on Friday, August 8th. BTIG Research raised their price objective on shares of Ginkgo Bioworks from $6.00 to $9.00 and gave the company a "sell" rating in a research note on Monday, August 25th. Finally, Wall Street Zen upgraded shares of Ginkgo Bioworks from a "sell" rating to a "hold" rating in a research report on Saturday, August 30th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $9.50.

Ginkgo Bioworks Trading Up 3.6%

Shares of NYSE DNA traded up $0.37 during midday trading on Thursday, reaching $10.66. 1,009,259 shares of the stock were exchanged, compared to its average volume of 1,539,266. The company has a market capitalization of $630.95 million, a P/E ratio of -1.82 and a beta of 1.50. Ginkgo Bioworks Holdings, Inc. has a 52-week low of $5.00 and a 52-week high of $16.85. The stock has a 50 day moving average price of $12.10 and a 200-day moving average price of $9.26.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($1.10) EPS for the quarter, topping analysts' consensus estimates of ($1.44) by $0.34. The business had revenue of $49.60 million during the quarter, compared to the consensus estimate of $41.60 million. Ginkgo Bioworks had a negative net margin of 136.56% and a negative return on equity of 43.25%. Ginkgo Bioworks has set its FY 2025 guidance at EPS. On average, analysts forecast that Ginkgo Bioworks Holdings, Inc. will post -10.02 earnings per share for the current year.

Ginkgo Bioworks Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.